[8-K] Entera Bio Ltd. Reports Material Event

Rhea-AI Filing Summary

Entera Bio Ltd. furnished a Current Report on Form 8-K stating that on August 8, 2025 the company issued a press release announcing its financial results and business updates for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02 and Item 7.01 of the report. The filing clarifies that the information is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act and therefore is not automatically subject to the liabilities of that section or to incorporation by reference in other filings unless explicitly done so.

Insights

Securities Analyst

TL;DR: Routine disclosure of quarterly results; no financial details provided in the filing itself.

The Form 8-K indicates Entera Bio furnished a press release with financial results for Q2 2025 as Exhibit 99.1. The report is procedural: it notifies investors that results were released and clarifies the exhibit is "furnished" not "filed." Because the 8-K text does not include revenue, profit, cash, or guidance figures, there is no new quantitative information in this filing for valuation or modeling. Materiality depends on the content of Exhibit 99.1, which is not included in the body of this 8-K.

Corporate Governance Expert

TL;DR: Proper Form 8-K disclosure practices followed; no governance or control changes disclosed.

The filing complies with disclosure rules by furnishing the press release and applying Regulation FD language. It does not report governance changes, executive departures, or other Items that would require different or additional disclosures. Investors must consult Exhibit 99.1 for substantive operational or financial information; absent that exhibit in the filing text, governance implications cannot be assessed from this document alone.

false000163809700-00000009722-532-7151Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary ShareENTXWNASDAQNASDAQ00016380972025-08-082025-08-080001638097entx:OrdinarySharesParValueOfNIS00000769Member2025-08-082025-08-080001638097entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember2025-08-082025-08-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2025

Entera Bio Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Israel		001-38556		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification)

KIRYAT HADASSAH, MINRAV BUILDING – FIFTH FLOOR, JERUSALEM, Israel 9112002
(Address of principal executive offices) (Zip Code)

+972-2-532-7151

(Registrant’s Telephone Number, Including Area Code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value of NIS 0.0000769		ENTX		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2025, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.

Item 7.01 Regulation FD Disclosure.

The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.

The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated August 8, 2025 announcing the Company’s financial results and business updates for the three months ended June 30, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ENTERA BIO LTD.
Date: August 8, 2025	By:	/s/ Miranda Toledano
		Name: Miranda Toledano Title: Chief Executive Officer